NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis

NASDAQ:NBIX • US64125C1099

124.12 USD
+1.02 (+0.83%)
At close: Feb 13, 2026
124 USD
-0.12 (-0.1%)
After Hours: 2/13/2026, 9:29:07 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to NBIX. NBIX was compared to 523 industry peers in the Biotechnology industry. NBIX gets an excellent profitability rating and is at the same time showing great financial health properties. NBIX is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make NBIX a good candidate for value and quality investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year NBIX was profitable.
  • In the past year NBIX had a positive cash flow from operations.
  • Of the past 5 years NBIX 4 years were profitable.
  • Of the past 5 years NBIX 4 years had a positive operating cash flow.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • NBIX's Return On Assets of 10.03% is amongst the best of the industry. NBIX outperforms 93.69% of its industry peers.
  • NBIX has a Return On Equity of 14.25%. This is amongst the best in the industry. NBIX outperforms 94.26% of its industry peers.
  • NBIX has a Return On Invested Capital of 11.10%. This is amongst the best in the industry. NBIX outperforms 94.84% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NBIX is significantly below the industry average of 18.27%.
Industry RankSector Rank
ROA 10.03%
ROE 14.25%
ROIC 11.1%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

  • Looking at the Profit Margin, with a value of 15.95%, NBIX belongs to the top of the industry, outperforming 92.16% of the companies in the same industry.
  • NBIX's Profit Margin has improved in the last couple of years.
  • NBIX has a better Operating Margin (20.64%) than 94.84% of its industry peers.
  • In the last couple of years the Operating Margin of NBIX has declined.
  • NBIX has a better Gross Margin (98.37%) than 97.71% of its industry peers.
  • NBIX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.64%
PM (TTM) 15.95%
GM 98.37%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NBIX is destroying value.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 7.42 indicates that NBIX is not in any danger for bankruptcy at the moment.
  • NBIX's Altman-Z score of 7.42 is fine compared to the rest of the industry. NBIX outperforms 78.01% of its industry peers.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.42
ROIC/WACC0.9
WACC12.27%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • A Current Ratio of 3.38 indicates that NBIX has no problem at all paying its short term obligations.
  • NBIX's Current ratio of 3.38 is in line compared to the rest of the industry. NBIX outperforms 40.73% of its industry peers.
  • NBIX has a Quick Ratio of 3.27. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.27, NBIX is in line with its industry, outperforming 41.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.27
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 53.80% over the past year.
  • Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 31.23% on average per year.
EPS 1Y (TTM)53.8%
EPS 3Y48.99%
EPS 5Y31.23%
EPS Q2Q%88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%28.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.06% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 9.62% on average over the next years. This is quite good.
EPS Next Y44.76%
EPS Next 2Y32.59%
EPS Next 3Y39.84%
EPS Next 5Y25.06%
Revenue Next Year19.46%
Revenue Next 2Y13.9%
Revenue Next 3Y12.69%
Revenue Next 5Y9.62%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 24.53, NBIX is valued on the expensive side.
  • Based on the Price/Earnings ratio, NBIX is valued cheaper than 93.88% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of NBIX to the average of the S&P500 Index (27.97), we can say NBIX is valued inline with the index average.
  • Based on the Price/Forward Earnings ratio of 16.95, the valuation of NBIX can be described as correct.
  • Based on the Price/Forward Earnings ratio, NBIX is valued cheaply inside the industry as 95.03% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 27.96. NBIX is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 24.53
Fwd PE 16.95
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 94.65% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, NBIX is valued cheaper than 95.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.87
EV/EBITDA 17.8
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NBIX has a very decent profitability rating, which may justify a higher PE ratio.
  • NBIX's earnings are expected to grow with 39.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.55
PEG (5Y)0.79
EPS Next 2Y32.59%
EPS Next 3Y39.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NBIX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (2/13/2026, 9:29:07 PM)

After market: 124 -0.12 (-0.1%)

124.12

+1.02 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-04
Inst Owners99.58%
Inst Owner Change-0.07%
Ins Owners1.01%
Ins Owner Change0.94%
Market Cap12.38B
Revenue(TTM)N/A
Net Income(TTM)428.00M
Analysts84
Price Target182.16 (46.76%)
Short Float %3.58%
Short Ratio3.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)0.17%
PT rev (3m)5.64%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)2.65%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)1.35%
Revenue NQ rev (1m)-1.34%
Revenue NQ rev (3m)-1.39%
Revenue NY rev (1m)-0.34%
Revenue NY rev (3m)-0.34%
Valuation
Industry RankSector Rank
PE 24.53
Fwd PE 16.95
P/S 4.61
P/FCF 20.87
P/OCF 19.43
P/B 4.12
P/tB 4.17
EV/EBITDA 17.8
EPS(TTM)5.06
EY4.08%
EPS(NY)7.32
Fwd EY5.9%
FCF(TTM)5.95
FCFY4.79%
OCF(TTM)6.39
OCFY5.15%
SpS26.91
BVpS30.12
TBVpS29.77
PEG (NY)0.55
PEG (5Y)0.79
Graham Number58.56
Profitability
Industry RankSector Rank
ROA 10.03%
ROE 14.25%
ROCE 15.26%
ROIC 11.1%
ROICexc 16.02%
ROICexgc 16.25%
OM 20.64%
PM (TTM) 15.95%
GM 98.37%
FCFM 22.11%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 147.14%
Cap/Sales 1.63%
Interest Coverage 250
Cash Conversion 109.17%
Profit Quality 138.57%
Current Ratio 3.38
Quick Ratio 3.27
Altman-Z 7.42
F-Score5
WACC12.27%
ROIC/WACC0.9
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)53.8%
EPS 3Y48.99%
EPS 5Y31.23%
EPS Q2Q%88%
EPS Next Y44.76%
EPS Next 2Y32.59%
EPS Next 3Y39.84%
EPS Next 5Y25.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%28.33%
Revenue Next Year19.46%
Revenue Next 2Y13.9%
Revenue Next 3Y12.69%
Revenue Next 5Y9.62%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year4.31%
EBIT Next 3Y21.9%
EBIT Next 5Y18.34%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%

NEUROCRINE BIOSCIENCES INC / NBIX FAQ

What is the fundamental rating for NBIX stock?

ChartMill assigns a fundamental rating of 6 / 10 to NBIX.


What is the valuation status for NBIX stock?

ChartMill assigns a valuation rating of 8 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.


What is the profitability of NBIX stock?

NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for NBIX stock?

The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 24.53 and the Price/Book (PB) ratio is 4.12.